BEGIN:VCALENDAR
VERSION:2.0
PRODID:www.eu-parc.eu
BEGIN:VEVENT
UID:69f3b1582b051
DTSTART:20260603T153000Z
SEQUENCE:0
TRANSP:OPAQUE
DTEND:20260603T170000Z
SUMMARY:Immunotoxicity Assessment in Drug Development
CLASS:PUBLIC
DESCRIPTION:This webinar provides an up-to-date overview of key development
 s in immunotoxicology\, with a focus on their implications for drug develo
 pment. It examines the range of immune-related adverse effects\, from infl
 ammation to autoimmunity\, and outlines the nonclinical assays and testing
  strategies used to identify and characterise these risks. The session als
 o reviews current regulatory guidance relevant to immunotoxicity assessmen
 t\, supporting a more consistent and science-based approach to safety eval
 uation.Target audienceThis session is intended for toxicologists\, nonclin
 ical safety scientists\, and professionals involved in drug development an
 d regulatory assessment. It is particularly relevant for those working in 
 pharmaceutical R&amp\;D\, contract research organisations\, and regulatory
  agencies who need to evaluate or interpret immunotoxicity data in a precl
 inical context.
X-ALT-DESC;FMTTYPE=text/html:<!doctype html><html><body><p>This webinar pro
 vides an up-to-date overview of key developments in immunotoxicology\, wit
 h a focus on their implications for drug development. It examines the rang
 e of immune-related adverse effects\, from inflammation to autoimmunity\, 
 and outlines the nonclinical assays and testing strategies used to identif
 y and characterise these risks. The session also reviews current regulator
 y guidance relevant to immunotoxicity assessment\, supporting a more consi
 stent and science-based approach to safety evaluation.</p><p><strong>Targe
 t audience</strong><br>This session is intended for toxicologists\, noncli
 nical safety scientists\, and professionals involved in drug development a
 nd regulatory assessment. It is particularly relevant for those working in
  pharmaceutical R&amp\;D\, contract research organisations\, and regulator
 y agencies who need to evaluate or interpret immunotoxicity data in a prec
 linical context.</p></body></html>
DTSTAMP:20260430T194528Z
END:VEVENT
END:VCALENDAR